JKC-363 is a selective melanocortin MC4 receptor antagonist with 90-fold higher affinity for the MC4 receptor (IC50 = 0.5 nM) than for the MC3 receptor (IC50 = 44.9 nM); it blocks α-MSH-induced stimulation of TRH release and exhibits antinociceptive effects.